Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020323 | 0.92 | HTR2A (0.46) | HTR2AHTR2CHTR2BPNMTAKR1C3 | |
| SCHEMBL11434101 | 0.84 | HTR2A (0.42) | HTR2AHTR2CHTR2BPNMTHTR7 | |
| SCHEMBL29991420 | 0.78 | MAOA (0.55) | HTR2AHTR2CHTR2BNOTUMDRD2 | |
| SCHEMBL2625798 | 0.78 | MAOA (0.55) | HTR2AHTR2CHTR2BNOTUMDRD2 | |
| SCHEMBL12836477 | 0.77 | HTR2A (0.46) | HTR2AHTR2CHTR2BPNMTAKR1C3 | |
| SCHEMBL13068138 | 0.77 | KMT2A (0.41) | HTR2AHTR2BAKR1C3NOTUMROCK1 | |
| SCHEMBL10534315 | 0.74 | CETP (0.48) | HTR2AHTR2CHTR2BPNMTAKR1C3 | |
| SCHEMBL3156676 | 0.74 | ACACB (0.51) | TMEM97SIGMAR1ACACB | |
| SCHEMBL160943 | 0.74 | HTR2A (0.55) | HTR2AHTR2CHTR2BPNMTNOTUM | |
| SCHEMBL6883015 | 0.73 | MAOA (0.59) | HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730840-B2 | Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agents | FLORIDA A&M UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190100495-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE ETHYLBENZAMIDE ANTI-CANCER AGENTS | FLORIDA A&M UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100495-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE ETHYLBENZAMIDE ANTI-CANCER AGENTS | BRDT, ESR2, TEAD4 | HTR2A 1740/4885HTR2C 1743/4885HTR2B 637/4885 |
| US-10730840-B2 | Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agents | BRDT, ESR2, TEAD4 | HTR2A 1740/4885HTR2C 1743/4885HTR2B 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.